Can you provide the average price target for MURAL ONCOLOGY PLC stock?
6 analysts have analysed MURA and the average price target is 6.12 USD. This implies a price increase of 200% is expected in the next year compared to the current price of 2.04.
MURAL ONCOLOGY PLC (MURA) Forecast, Price Target & Analyst Ratings
NASDAQ:MURA • IE000LK2BOB4
Current stock price
2.04 USD
0 (0%)
At close:
2.03 USD
-0.01 (-0.49%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MURAL ONCOLOGY PLC (MURA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$0.38
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$6.12
Upside
+ 200.00%
From current price of $2.04 to mean target of $6.12, Based on 6 analyst forecasts
Low
$6.06
Median
$6.12
High
$6.30
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for MURA. The average price target is 6.12 USD. This implies a price increase of 200% is expected in the next year compared to the current price of 2.04.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
MURA was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about MURA.
In the previous month the buy percentage consensus was at a similar level.
MURA was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-03-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-25 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-27 | Jones Trading | Initiate | Buy |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-17 | HC Wainwright & Co. | Initiate | Buy |
| 2024-10-04 | Raymond James | Initiate | Strong Buy |
| 2024-06-28 | Rodman & Renshaw | Initiate | Buy |
| 2024-04-04 | Morgan Stanley | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$0.38
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 81.22%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
65.42%
Next Earnings Summary
Full Analyst Estimates 2025 - 2032
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 34.35% | N/A 54.75% | N/A 305.61% | N/A 24.35% | |||||
| EBITDA YoY % growth | -173.87M | -183.42M -5.49% | -193.671M -5.59% | -134.75M 30.42% | N/A 25.05% | N/A 94.03% | N/A 79.15% | N/A -5,945.45% | N/A 9.64% | N/A 34.87% | N/A 414.65% | N/A 34.29% | |
| EBIT YoY % growth | -175.37M | -184.92M -5.45% | -196.238M -6.12% | -138.262M 29.54% | N/A 25.13% | N/A 92.12% | N/A 62.50% | N/A -3,660.67% | N/A -5.25% | N/A 44.27% | N/A 74.32% | N/A 426.25% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -7.58 | N/A 23.84% | N/A 93.11% | N/A 69.23% | N/A -1,725.00% | N/A 17.81% | N/A 34.44% | N/A 318.22% | N/A 52.23% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.38 81.22% | -0.83 57.19% | -0.88 50.16% | -0.90 -327.43% | -0.79 -108.11% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -30.722M 5.01% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -31.059M 13.37% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
25.65%
EPS Next 5 Year
11.94%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
25.80%
EBIT Next 5 Year
8.57%
MURAL ONCOLOGY PLC / MURA Forecast FAQ
Can you provide the consensus estimates for MURAL ONCOLOGY PLC next earnings?
The consensus EPS estimate for the next earnings of MURAL ONCOLOGY PLC (MURA) is -0.38 USD and the consensus revenue estimate is 0 USD.